

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

INSIDE INFORMATION PROFIT WARNING

This announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended 31 December 2024 (the “**Reporting Period**”) and information currently available to the Board, it is expected that the net profit for the Reporting Period would be decreased to not more than RMB30.0 million as compared with that of RMB55.0 million for the year ended 31 December 2023 (the “**Corresponding Period**”) primarily due to

- (i) the increase in administrative expenses caused by the grant of share awards pursuant to the share award scheme adopted by the Company, with the aim to recognize the contributions of key talents, to provide them with incentives for retention to ensure ongoing operation and development of the Group, and to attract suitable personnel for further growth;
- (ii) the absence of fair value gains on convertible redeemable preferred shares which amounted to approximately RMB12.8 million for the Corresponding Period;

- (iii) a decrease in revenue of the Group during the Reporting Period as compared to that of the Corresponding Period, mainly attributable to the delays in project execution by customers, caused by their prolonged decision-making time under the prevailing macroeconomic conditions; and
- (iv) the increase in administrative expenses associated with the Group's ongoing international expansion efforts to explore business development opportunities overseas, including Japan, Singapore and Vietnam. The Company is committed to intensifying its international expansion efforts and actively seeking global business growth opportunities. While these initiatives may lead to a temporary increase in administrative costs in the short term, they are essential investments that will provide a broader scope for future international development. By recognising and leveraging potential markets, the Group aims to enhance its competitiveness and ensure sustainable growth in the evolving global landscape.

Notwithstanding the above, the Company is expected to remain profitable during the Reporting Period. Despite short-term fluctuations in profitability, the Company's overall operations remain robust. The Company will continue to optimize its resource allocation and operations to ensure its sustainable growth. The Board is confident in the Group's development prospects and will remain committed to drive long-term value for the Shareholders.

As the results for the Reporting Period have not been finalized, the information contained in this announcement is only a preliminary assessment by the Board based on information currently available including the unaudited consolidated management accounts of the Group for the Reporting Period, which have not been confirmed, reviewed or audited by the auditor of the Company. Such financial information will be subject to finalisation and necessary adjustments. The details of the annual results of the Group for the Reporting Period will be disclosed in the annual results announcement of the Company, which is expected to be published by the end of March 2025.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

Dr. Zhang Fabao
Chairman of the Board and Executive Director

Hong Kong, 21 March 2025

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Wang Shuai and Mr. Cheng Liang as executive Directors; Ms. Wang Xin and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.